UPDATE: Emergent To Acquire Adapt Pharma For $735M Total Consideration Consisting Of Upfront Payment Of $635M And Up To $100M In Cash For Potential Sales-Based Milestones; Upfront Payment Includes $575M In Cash And $60M Emergent Common Stock
Benzinga Newsdesk